Table 1.
Non-malignant brain biopsy-confirmed inflammatory-demyelination: Study Cohort
| Demographics | (n=29) |
|
| |
| Age in years, mean (Range) | 41.4 (16–69) |
|
| |
| Sex (%female) | 51.7% |
|
| |
| Race/Ethnicity | |
|
| |
| Caucasian | 13 (44.8%) |
|
| |
| Asian | 6 (20.7%) |
|
| |
| Black | 2 (6.9%) |
|
| |
| Other/Unknown | 8 (27.6%) |
|
| |
| Clinical History | |
|
| |
| Prior Demyelination Events | 3 (10.3%) |
|
| |
| Prior Neurologic History* | 8 (27.6%) |
|
| |
| Radiographic Features | |
|
| |
| Lesion Number | |
|
| |
| Solitary | 12 (41.4%) |
|
| |
| Multifocal | 17 (58.6%) |
|
| |
| Edema | 23 (79.3%) |
|
| |
| Enhancement | 28 (96.6%) |
|
| |
| Incomplete Rim | 22 (75.9%) |
|
| |
| Nodular | 4 (13.8%) |
|
| |
| Patchy | 2 (6.9%) |
|
| |
| Radiating/Linear | 2 (6.9%) |
|
| |
| Complete Rim | 1 (3.4%) |
|
| |
| Spinal Lesions (n=24) | 6 (25%) |
| Laboratory Features | |
| Serum anti-AQP4 IgG (n=13) | 0 (0%) |
|
| |
| Treatment | |
|
| |
| Glucocorticoids | 20 (69.0%) |
|
| |
| Plasma Exchange | 14 (48.1%) |
|
| |
| Immunosuppressive therapy (n=21) | 15 (71.4%) |
|
| |
| Prognosis | |
|
| |
| Follow-up duration, months (median) | 22 |
|
| |
| Clinical Relapse | |
|
| |
| All Subjects# | 8 (40%) |
|
| |
| ≥12 months follow-up (n=16) | 7 (43.8%) |
|
| |
| MRI Progression (n=22) | |
|
| |
| All Subjects | 9 (40.9%) |
|
| |
| ≥12 months follow-up (n=16) | 6 (37.5%) |
|
| |
| Recurrent TDL | 3 (13.6%) |
|
| |
| Last EDSS, mean (SD) | 3.5 (2.4) |
*
Prior Neurological History included suspected stroke (n=1), seizure disorder (n=3), autoimmune encephalitis (n=1), facial palsy (n=1), paraparesis (n=1), optic neuritis (n=1).
#
20 patients with available follow-up.